Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firsekibart
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Firsekibart (SHR-1305) is a humanized monoclonal antibody designed to target and neutralize interleukin-1 beta (IL-1β). Developed by Jiangsu Hengrui Pharmaceuticals, it is primarily being investigated for the treatment of acute gouty arthritis and the prevention of gout flares. By binding specifically to IL-1β, firsekibart prevents the cytokine from interacting with its receptor, thereby inhibiting the pro-inflammatory signaling cascade that drives the intense pain and inflammation characteristic of gout attacks. The drug is typically administered via subcutaneous injection and has progressed into Phase 3 clinical trials for gout-related indications.
- Brand names
- Jinbeixin金蓓欣金贝新
- Other names
- genakumabkinnazumab伏欣奇拜单抗
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on firsekibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firsekibart.